The annual JPMorgan Healthcare Conference, often called the Superbowl of biotech, kicks off this week.
The Motley Fool has you covered with reports on company presentations and themes from the conferences. Check back daily for updates:
- 3 Biotech Stocks We're Watching Closest Ahead of the JPMorgan Healthcare Conference
- Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
- 15 Numbers That Will Make Johnson & Johnson Investors Giddy
- Why Pharmacyclics Inc. Skyrocketed Higher Today
- Celgene Corporation's Future: Everything You Need to Know in 5 Slides
- 7 Things Amgen Corporation's CEO Wants You to Know
- Gilead Sciences, Inc. Is No Longer Just an HIV Company
- Why Investors Are Excited About Intrexon and Xiopharm's New Deal
- AbbVie Inc's Insights at the JP Morgan Healthcare Conference
- 5 Reasons Rite Aid Corporation's Rebound Isn't Over Yet
- 3 Slides That Tell You Everything You Need to Know About GlaxoSmithKline PLC
- Vertex Pharmaceuticals Going to Get Fat on Cystic Fibrosis Pie
- Can AbbVie Inc. Overcome Humira's Looming Patent Expiration?
- Medical Marijuana Goes Wall Street
- MannKind Corporation on Track for Afrezza Launch
More from The Motley Fool:
The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.